For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...

Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could ...

Scientists have uncovered new genetic rules that determine whether the immune system’s “killer” T cells remain powerful long-term defenders or become worn out and ineffective. By building a detailed ...

As populations age worldwide, the decline of the immune system, a process known as immunosenescence, has become a critical ...

Despite improvements in therapies, multiple myeloma (MM) is a disease that will always relapse. Why is this? What is the key to finding effective therapies to cure MM? Evan Newell, a Professor in the ...

Sickle cell disease (SCD) altered CD8+ T-cell chromatin architecture, triggering ferroptosis and weakening antitumor immunity. Hydrogen sulfide (H2S) treatment restored chromatin interactions and ...

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...